title: Safety and efficacy of rituximab in steroid-refractory chronic GVHD.
authors.forename: A
authors.initials: A
authors.lastname: Clavert
authors.forename: P
authors.initials: P
authors.lastname: Chevallier
authors.forename: T
authors.initials: T
authors.lastname: Guillaume
authors.forename: J
authors.initials: J
authors.lastname: Delaunay
authors.forename: S
authors.initials: S
authors.lastname: Le Gouill
authors.forename: B
authors.initials: B
authors.lastname: Mahe
authors.forename: V
authors.initials: V
authors.lastname: Dubruille
authors.forename: T
authors.initials: T
authors.lastname: Gastinne
authors.forename: N
authors.initials: N
authors.lastname: Blin
authors.forename: P
authors.initials: P
authors.lastname: Moreau
authors.forename: M
authors.initials: M
authors.lastname: Mohty
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy*; D006801:Humans; D008297:Male; D008875:Middle Aged; D000069283:Rituximab; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D000069283:Rituximab